Core Insights - Chengdu XianDao is a platform-based R&D enterprise focused on new drug discovery, aiming to build a scalable, efficient, and expandable drug discovery system [1][4] - The company utilizes a leading trillion-level DNA-encoded compound library (DEL) as its core technology platform, empowering over 1,000 R&D projects for more than 600 global clients [1][4] - Future strategies include deepening the R&D value chain with AI and automation technologies, while also expanding capabilities horizontally [1][4] Group 1: Company Strategy and R&D Focus - The core strategy involves creating a scalable and efficient drug discovery system centered around the DEL technology platform [4] - The company aims to explore new types of tool molecules and therapeutic molecules, focusing on discovery, optimization, and transformation [1][4] - The DEL technology is being applied to challenging target areas such as PPI and GPCR, enhancing the breadth and depth of target exploration [5][6] Group 2: HAILO Platform and AI Integration - The HAILO platform integrates DEL, AI, and automation for molecular optimization, enhancing data integration and molecular optimization efficiency [2][7] - The AI assistant HANDS facilitates a closed-loop system from data acquisition to business implementation, improving R&D efficiency [8][9] - HAILO's high-throughput capabilities support the entire process from target validation to lead compound optimization, significantly improving overall efficiency [9] Group 3: Clinical Development and Pipeline - The self-developed project HG146 is in Phase II clinical trials for recurrent or metastatic adenoid cystic carcinoma, with positive preliminary efficacy and safety signals [10] - The company is preparing to communicate with the National Medical Products Administration (CDE) regarding the next steps for HG146's development and registration [10] - The subsidiary Xianyan Biotech is advancing its pipeline, with LDR2402 entering Phase II clinical trials and LDR2515's IND application accepted by CDE [11] Group 4: M&A and Investment Strategy - The company is cautiously evaluating investment or acquisition opportunities that enhance core business, extend the industry chain, or possess breakthrough technology potential [12][13] - The focus is on companies that can strengthen existing operations, extend to upstream and downstream of the industry chain, or are in emerging exploration stages [13] - The company aims to balance short-term goals with long-term strategies through systematic resource integration and market expansion [13]

本报记者 蒙婷婷 在成都双流区的成都先导药物开发股份有限公司（以下简称"成都先导"）总部实验室，数台灰白色冰箱常年维持在零下 20℃左右的恒温状态，其中储存的成千上万支试管中装着万亿级的DNA编码化合物——这正是成都先导核心DNA编码化合物 库（DEL）技术平台的"压舱石"，也是其新药发现能力的关键基石。 1月6日，成都先导迎来上市以来首届投资者开放日，以"万亿种子•智擎未来"为主题，通过战略解读、业务分享与实地参观 多环节联动，向资本市场全方位展现创新驱动的发展逻辑与长期成长潜力。 《证券日报》记者在现场看到，来自全国各地的机构投资者、个人投资者及卖方分析师齐聚一堂，与成都先导管理层及核 心研发团队展开深度交流，并走进核心实验室实地观摩DEL技术筛选、化学合成及数据分析全流程，直观感受公司技术实力， 深化对其技术领导力与价值前景的认知。 作为新分子发现领域的领军企业，核心技术平台是成都先导的核心竞争力所在。公司董事长、总经理李进在致辞中深入解 读"万亿种子"愿景，他明确表示："公司拥有全球已知公开最大的DNA编码化合物库（DEL）之一，分子数量突破万亿级。依 托DEL等四大核心技术平台，我们已构建起成熟的新 ...

Group 1: Industry Performance Overview - The performance forecast for Q3 2025 shows bright prospects in the electronics and basic chemicals sectors, with over 10 companies expected to achieve a profit growth rate exceeding 30% year-on-year [1] - The electronics sector is benefiting from the AI wave, which is driving new demand and maintaining high growth [1] - The basic chemicals industry is experiencing structural improvement due to supply constraints and demand support, with some sectors already showing signs of recovery [1] Group 2: Market Trends and Signals - The market has shifted from an upward trend to a volatile pattern, influenced by ongoing US-China trade conflicts, which negatively affect market risk appetite [2] - Technical indicators suggest a potential market rebound, with a recommendation to reduce positions to a neutral level while waiting for volume signals [2] - The industry allocation model indicates that dividend assets and sectors benefiting from policy support, such as photovoltaics and chemicals, remain worthy of attention [2] Group 3: Medical Equipment Sector Insights - The medical equipment sector reported a decline in revenue and net profit for H1 2025, with revenues down 7.3% and net profits down 27% year-on-year [6] - There is a significant recovery in bidding activities, with a 64% year-on-year increase in the total amount of domestic medical equipment bids in H1 2025 [6] - Companies like Yingli Medical and Mindray are seeing growth in overseas revenues, indicating a trend towards globalization [7] Group 4: Debt Market Analysis - The debt market is currently influenced by risk aversion, with a mixed performance observed due to trade tensions and equity market behavior [4] - The focus is on interest rate spreads and the potential for short-term trading opportunities, particularly around the upcoming 20th Central Committee meeting [4] Group 5: Future Growth Projections - The company is expected to achieve significant revenue growth in the coming years, with projected revenues of 46.45 billion, 56.84 billion, and 71.74 billion yuan from 2025 to 2027 [12] - The lithium battery equipment sector is anticipated to see a compound annual growth rate (CAGR) of 34% in overseas revenue from 2020 to 2024, indicating strong international demand [14] - The new drug development sector is expected to grow steadily, with projected revenues of 5.04 billion, 6.08 billion, and 7.39 billion yuan from 2025 to 2027 [17]

Group 1: Research Basic Information - The research object is Chengdu先导, belonging to the medical service industry, and the reception time is September 23, 2025. The listed company's reception staff includes the chairman, general manager JIN LI (Li Jin), independent director Tang Guoqiong, financial director Liu Hongge, and board secretary Geng Shiwei [16] Group 2: Detailed Research Institutions - The reception object is investors who participated in the company's 2025 semi - annual performance briefing through the "Shanghai Stock Exchange Roadshow Center" online platform [19] Group 3: Core Views - In the first half of 2025, the company's operating income increased by 16.58% year - on - year, and the net profit attributable to the parent increased by 390.72%. The main driving factors include the growth of the DEL sector, milestone income confirmation, exploration of new business models, and the efficient operation of the automation platform. Additionally, government subsidies and exchange gains also contributed to the profit [23] - The DEL technology platform continued to expand its library types in 2025, built large - scale peptide libraries, made progress in screening, and participated in important international cooperation projects, which demonstrated its leading position [25] - The company adjusted the R & D investment structure, with the parent company increasing investment and the UK subsidiary decreasing it, achieving a slight decline in overall R & D expenses while improving resource allocation efficiency [26] - The company adjusted its self - developed pipeline projects. The HG146 project is advancing smoothly in clinical phase II, other projects are also progressing steadily, and some projects have achieved important milestones [27] - The "HAILO platform" achieved phased results in platform construction, model iteration, and pipeline promotion in the first half of 2025 [28] - The company joined the global first DNA - encoded compound library (DEL) alliance as the only technology service provider, and the alliance has made good progress in the past year [30]

Group 1 - The company achieved revenue of 227 million yuan in H1 2025, representing a growth of 16.58%, and a net profit attributable to shareholders of 50 million yuan, up 390.72% [1] - In Q2 alone, the company reported revenue of 120 million yuan, an increase of 37.71%, and a net profit attributable to shareholders of 22 million yuan, up 681.39% [1] - The overall gross margin for H1 2025 was 53.81%, an increase of 7.18 percentage points, and the net profit margin was 21.82%, up 17.05 percentage points, indicating a strong recovery in profitability [2] Group 2 - The DEL business segment continued to grow rapidly, with revenue of 102 million yuan in H1 2025, an increase of 40.45%, driven mainly by the growth of customized library services [2] - The company is advancing in new drug discovery and optimization through its DEL+AI/ML projects, achieving significant milestones in model and data development, high-throughput chemical platforms, and project pipelines [3] - The company has initiated two self-developed projects based on the HAILO platform, which have entered the evaluation stage for lead compounds [3] Group 3 - Revenue projections for the company from 2025 to 2027 are estimated at 507 million yuan, 609 million yuan, and 735 million yuan, with year-on-year growth rates of 18.83%, 20.10%, and 20.65% respectively [4] - The net profit attributable to shareholders is expected to be 78 million yuan, 111 million yuan, and 136 million yuan for the same period, with growth rates of 52.32%, 41.88%, and 22.47% respectively [4]

Core Insights - Chengdu XianDao reported a significant increase in revenue and net profit for H1 2025, with revenue reaching 227 million yuan, up 16.59% year-on-year, and net profit of 50 million yuan, up 390.59% year-on-year [1] - The company's gross margin improved to 53.81%, an increase of 7.18 percentage points year-on-year, while the net profit margin rose to 22.04%, up 16.80 percentage points year-on-year [1] Financial Performance - For Q2 2025, the company achieved revenue of 120 million yuan, a year-on-year increase of 37.71%, but net profit decreased to 22 million yuan, down 681.82% year-on-year [1] - R&D expenses for H1 2025 were 29 million yuan, a decrease of 6.28% year-on-year, as the company adjusted its R&D resource allocation to focus on commercial projects [2] Business Segments - The DEL segment outperformed expectations with revenue of 102 million yuan, up 40.45% year-on-year, driven by strong progress in customized libraries [2] - The FBDD/SBDD segment generated revenue of 65 million yuan, a 4.15% increase year-on-year, mainly due to milestone revenue recognized by the UK subsidiary Vernalis [2] - The OBT segment saw revenue of 28 million yuan, down 3.35% year-on-year, while the TPD segment's revenue was 7 million yuan, down 8.67% year-on-year due to project execution timelines [2] Technological Advancements - The company is advancing its AI capabilities in drug discovery, with the HAILO platform achieving significant milestones in model and data development, high-throughput chemical platform integration, and project pipeline initiation [3] - New self-research projects have been launched based on the HAILO platform, entering the evaluation and optimization stages [3] Future Outlook - The company aims for continued global expansion and operational efficiency, projecting revenues of 515 million yuan, 617 million yuan, and 740 million yuan for 2025-2027, with year-on-year growth rates of 20.6%, 19.9%, and 19.9% respectively [4] - Expected net profits for the same period are 90 million yuan, 107 million yuan, and 131 million yuan, with growth rates of 75.5%, 19.0%, and 22.0% respectively [4]